一名患有胸腺鳞状细胞癌并伴有多处肺转移的患者对抗程序性死亡蛋白1（anti-PD-1）治疗产生显著反应。
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
作者信息
Yang Yan, Ding Liren, Wang Pingli
机构信息
Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
出版信息
J Thorac Dis. 2016 Jul;8(7):E535-7. doi: 10.21037/jtd.2016.06.32.
Abstract
Immunotherapy directed at the programmed cell death-1 receptor (PD-1) or its ligand PD-L1 has demonstrated efficacy in some malignancies, such as metastatic melanoma and non-small-cell lung cancer (NSCLC). Compared with cytotoxic chemotherapy, radiotherapy or molecular targeted agent, it is an innovative way to treat malignancies with durable clinical responses and manageable adverse. We present a case of female patient with squamous cell carcinoma of thymus involving multiple lung metastases, who was successfully treated with anti-PD-1 monoclonal antibody, pembrolizumab.
摘要
针对程序性细胞死亡蛋白1受体（PD-1）或其配体PD-L1的免疫疗法已在某些恶性肿瘤中显示出疗效，如转移性黑色素瘤和非小细胞肺癌（NSCLC）。与细胞毒性化疗、放疗或分子靶向药物相比，它是一种治疗恶性肿瘤的创新方法，具有持久的临床反应和可控的不良反应。我们报告一例患有胸腺鳞状细胞癌并伴有多发肺转移的女性患者，该患者通过抗PD-1单克隆抗体帕博利珠单抗成功治愈。
相似文献
1
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
J Thorac Dis. 2016 Jul;8(7):E535-7. doi: 10.21037/jtd.2016.06.32.
2
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Front Oncol. 2020 Aug 18;10:1478. doi: 10.3389/fonc.2020.01478. eCollection 2020.
3
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.
4
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4.
5
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.
Drugs Context. 2015 Oct 14;4:212289. doi: 10.7573/dic.212289. eCollection 2015.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Oncologist. 2016 May;21(5):643-50. doi: 10.1634/theoncologist.2015-0498. Epub 2016 Mar 29.
8
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
9
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
10
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
引用本文的文献
1
Current immunotherapy for thymic epithelial tumors: a narrative review.
Mediastinum. 2024 Oct 11;8:47. doi: 10.21037/med-24-24. eCollection 2024.
2
Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review.
Biomedicines. 2023 Oct 8;11(10):2722. doi: 10.3390/biomedicines11102722.
3
Current Treatment Approaches for Thymic Epithelial Tumors.
Life (Basel). 2023 May 12;13(5):1170. doi: 10.3390/life13051170.
4
Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors.
Cancers (Basel). 2022 Dec 31;15(1):289. doi: 10.3390/cancers15010289.
5
A single-center analysis of 71 patients with thymic carcinoma: the chronological changes in the surgical procedure and prognosis.
J Thorac Dis. 2022 Sep;14(9):3211-3220. doi: 10.21037/jtd-22-490.
6
Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment.
Int J Mol Sci. 2022 Jul 16;23(14):7864. doi: 10.3390/ijms23147864.
7
Molecular predictors of response to pembrolizumab in thymic carcinoma.
Cell Rep Med. 2021 Sep 3;2(9):100392. doi: 10.1016/j.xcrm.2021.100392. eCollection 2021 Sep 21.
8
The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.
J Thorac Dis. 2021 Aug;13(8):5093-5103. doi: 10.21037/jtd-21-290.
9
A CRISPR View of Biological Mechanisms.
Discoveries (Craiova). 2016 Dec 31;4(4):e69. doi: 10.15190/d.2016.16.
10
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
J Clin Med. 2019 Nov 1;8(11):1833. doi: 10.3390/jcm8111833.
本文引用的文献
1
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Urol Oncol. 2016 Apr;34(4):171-81. doi: 10.1016/j.urolonc.2016.01.006. Epub 2016 Feb 28.
2
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Am J Health Syst Pharm. 2016 Feb 15;73(4):193-201. doi: 10.2146/ajhp140768.
3
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.
4
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015.
5
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
6
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
7
Toxicity of checkpoint inhibitors.
Chin Clin Oncol. 2014 Sep;3(3):31. doi: 10.3978/j.issn.2304-3865.2014.08.03.
8
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Lung Cancer. 2015 May;88(2):154-9. doi: 10.1016/j.lungcan.2015.03.003. Epub 2015 Mar 10.
9
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.
Zotero 插件